

# Huabin Hu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/736720/publications.pdf>

Version: 2024-02-01

67  
papers

647  
citations

759233

12  
h-index

642732

23  
g-index

70  
all docs

70  
docs citations

70  
times ranked

785  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 38-48.	8.1	111
2	mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis. <i>Clinical Colorectal Cancer</i> , 2022, 21, e12-e20.	2.3	6
3	A prognostic nomogram for intrahepatic progression-free survival in patients with colorectal liver metastases after ultrasound-guided percutaneous microwave ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 144-154.	2.5	5
4	mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial. <i>Annals of Translational Medicine</i> , 2022, 10, 171-171.	1.7	5
5	The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy. <i>Annals of Translational Medicine</i> , 2022, 10, 491-491.	1.7	6
6	Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3500-3500.	1.6	9
7	PD-1 blockade combined chemotherapy and bevacizumab in DNA mismatch repair-proficient/microsatellite stable colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15547-e15547.	1.6	0
8	PD-1 blockade boosted chemo-target therapy in cT4NxM0 pMMR/MSS colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15606-e15606.	1.6	0
9	Homologous recombination deficiency is linked to shorter survival expectancy in late-stage colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15576-e15576.	1.6	0
10	Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial. <i>Oncologist</i> , 2021, 26, e90-e98.	3.7	24
11	Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.. <i>Oncologist</i> , 2021, 26, e290-e297.	3.7	15
12	Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. <i>Advances in Therapy</i> , 2021, 38, 1650-1659.	2.9	6
13	Clinicopathologic features and impact of metastasectomy in patients with BRAF-mutant metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15547-e15547.	1.6	0
14	Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies. <i>Clinical Colorectal Cancer</i> , 2021, 20, e240-e248.	2.3	8
15	Abstract 2523: Novel genomic characterization in late stage colorectal cancer. , 2021, , .		0
16	Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1141-1147.	4.9	23
17	First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 77.	1.5	15
18	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1649.	2.8	32

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review. <i>Advances in Therapy</i> , 2020, 37, 4233-4248.	2.9	5
20	TRIBE2 results and toxicity. <i>Lancet Oncology</i> , The, 2020, 21, e298.	10.7	0
21	&lt;p&gt;Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3301-3310.	1.9	9
22	Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. <i>Advances in Therapy</i> , 2020, 37, 2116-2126.	2.9	24
23	NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. <i>Nature Communications</i> , 2020, 11, 1669.	12.8	93
24	Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. <i>Cancer Control</i> , 2020, 27, 107327482090227.	1.8	8
25	Prognostic and predictive value of DNA mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 210-210.	1.6	0
26	mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 99-99.	1.6	3
27	Comparing FOLFOXIRI plus bevacizumab with doublet chemotherapy plus anti-EGFR antibody: A systemic review and network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 97-97.	1.6	0
28	Induction chemotherapy with mFOLFOXIRI in cT4N+ locally advanced rectal cancer: Subgroup analysis from a prospective trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16136-e16136.	1.6	0
29	The prognosis valve of tumor regression grade in the same ypStage patients after neoadjuvant treatment in locally advanced rectal cancer: Post-hoc analysis of a prospective trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16129-e16129.	1.6	0
30	Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4075-4075.	1.6	0
31	PD-1 blockade combined with COX inhibitor in patients with MSI-H/dMMR or high TMB, advanced or metastatic colorectal cancer (PCOX study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 111-111.	1.6	2
32	Efficacy and safety of regorafenib in combination with chemotherapy as second-line therapy in patients with metastatic colorectal cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 115-115.	1.6	0
33	Neoadjuvant mFOLFOXIRI chemotherapy-improved survival benefit comparing with CRT in locally advanced rectal cancer: A propensity score matched analysis from two prospective trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 98-98.	1.6	0
34	Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 238-244.	2.3	29
35	Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. <i>Lung Cancer</i> , 2019, 138, 88-94.	2.0	54
36	Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. <i>Journal of Medical Economics</i> , 2019, 22, 584-592.	2.1	13

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of tyrosine kinase inhibition in first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e20504-e20504.	1.6	1
38	PD-1 antibody combined with COX inhibitor in MSI-h/dMMR or high TMB colorectal cancer: A single arm phase II study.. Journal of Clinical Oncology, 2019, 37, TPS729-TPS729.	1.6	0
39	Validation of neoadjuvant rectal cancer(NAR) score as a surrogate endpoint for disease free survival in Chinese FOWARC study.. Journal of Clinical Oncology, 2019, 37, e15162-e15162.	1.6	1
40	Cost-effectiveness for metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15003-e15003.	1.6	0
41	Effect of neoadjuvant treatment on locally advanced rectal mucinous adenocarcinoma or signet-ring cell carcinoma: A post-hoc analysis from 3 prospective studies.. Journal of Clinical Oncology, 2019, 37, 3608-3608.	1.6	0
42	CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial. BMC Cancer, 2018, 18, 1145.	2.6	22
43	The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer. Journal of Cancer, 2018, 9, 3109-3116.	2.5	9
44	Total neoadjuvant treatment versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective phase II clinical trials.. Journal of Clinical Oncology, 2018, 36, 3600-3600.	1.6	1
45	Totally neoadjuvant chemoradiation therapy with mFOLFOX6 in locally advanced rectal cancer: A single-arm phase II study (FOTAC).. Journal of Clinical Oncology, 2018, 36, 732-732.	1.6	1
46	Clinicopathological and genetic features of patients with colorectal cancer containing mucinous component.. Journal of Clinical Oncology, 2018, 36, e15661-e15661.	1.6	0
47	miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ $\beta$ -catenin/EMT signaling cascade in gastric cancer. BMC Cancer, 2017, 17, 886.	2.6	49
48	Colorectal cancer with mucinous component compared to clinicopathological and molecular features as mucinous adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, e15166-e15166.	1.6	3
49	Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial.. Journal of Clinical Oncology, 2017, 35, TPS820-TPS820.	1.6	0
50	Totally neoadjuvant chemoradiation therapy with mFOLFOX6 in locally advanced rectal cancer: A single arm phase II study (FOTAC).. Journal of Clinical Oncology, 2017, 35, TPS816-TPS816.	1.6	0
51	Neoadjuvant chemotherapy with mFOLFOXIRI alone for cT4 and fixed cT3 rectal cancer: Results from a single arm phase II study (FORTUNE).. Journal of Clinical Oncology, 2017, 35, 3607-3607.	1.6	1
52	Application and comparison of different implanted ports in malignant tumor patients. World Journal of Surgical Oncology, 2016, 14, 251.	1.9	9
53	FOLFOX or CAPOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced colon cancer: OPTICAL study.. Journal of Clinical Oncology, 2016, 34, TPS3637-TPS3637.	1.6	1
54	Association of nonsteroidal anti-inflammatory drugs and aspirin use and the risk of head and neck cancers: a meta-analysis of observational studies. Oncotarget, 2016, 7, 65196-65207.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Capecitabine maintenance therapy after adjuvant chemotherapy of FOLFOX (or XELOX) in patients with stage IIIC or R0 resected stage IV colorectal cancer (CAMCO study).. Journal of Clinical Oncology, 2016, 34, TPS781-TPS781.	1.6	0
56	Nomogram including pretherapeutic parameters for prediction of early response after neoadjuvant treatment in rectal cancer: Results from a prospective randomized study.. Journal of Clinical Oncology, 2016, 34, 716-716.	1.6	0
57	Neoadjuvant chemotherapy alone with mFOLFOXIRI in locally advanced rectal cancer: A single-arm phase II study.. Journal of Clinical Oncology, 2016, 34, TPS783-TPS783.	1.6	0
58	Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.. Journal of Clinical Oncology, 2016, 34, e23066-e23066.	1.6	0
59	CEA clearance pattern as a predictor for pathologic complete response after neoadjuvant chemoradiation for rectal cancer: Results of the FOWARC trial.. Journal of Clinical Oncology, 2016, 34, e15112-e15112.	1.6	0
60	Visceral adipose tissue and the risk of colorectal adenomas. European Journal of Cancer Prevention, 2015, 24, 462-469.	1.3	8
61	Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence " A retrospective single-center study. Gastroenterology Report, 2015, 3, gov051.	1.3	5
62	Bevacizumab, Aflibercept or Ramucirumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer following progression with Bevacizumab in first-line therapy: A systematic review and indirect comparison.. Journal of Clinical Oncology, 2015, 33, e14601-e14601.	1.6	1
63	FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.. Journal of Clinical Oncology, 2015, 33, TPS3624-TPS3624.	1.6	1
64	Folfoxiri with or without cetuximab as first-line treatment of patients with non-resectable liver, only metastatic colorectal cancer and KRAS/NRAS wild type (FOCULM study).. Journal of Clinical Oncology, 2015, 33, TPS798-TPS798.	1.6	1
65	A clinical parameters-based predictive model to predict early efficacy for rectal cancer patients with neoadjuvant chemotherapy alone: Subgroup efficacy analysis of a phase II study.. Journal of Clinical Oncology, 2015, 33, 716-716.	1.6	2
66	Nonsteroidal anti-inflammatory drug use and the risk of melanoma. European Journal of Cancer Prevention, 2014, 23, 62-68.	1.3	10
67	Long-course targeted therapy with bevacizumab to predict better survival in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2013, 31, e14704-e14704.	1.6	0